Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Gevaert, P; Lang-Loidolt, D; Lackner, A; Stammberger, H; Staudinger, H; Van Zele, T; Holtappels, G; Tavernier, J; van Cauwenberge, P; Bachert, C.
Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps.
J Allergy Clin Immunol. 2006; 118(5): 1133-1141.
Doi: 10.1016/j.jaci.2006.05.031
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Lackner Andreas
- Lang-Loidolt Doris
- Stammberger Heinz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Chronic rhinosinusitis with nasal polyps is characterized by an eosinophilic inflammation and high IL-5 levels. OBJECTIVES: Antagonizing the effect of IL-5 is a potential new treatment strategy in patients with nasal polyps. METHODS: In a double-blind, placebo-controlled, randomized, 2-center safety and pharmacokinetic study, 24 subjects with bilateral nasal polyps were randomized to receive a single intravenous infusion of reslizumab, a humanized anti-human IL-5 mAb, at 3 mg/kg or 1 mg/kg or placebo. We evaluated the safety and pharmacokinetics of reslizumab, and biologic activity was assessed by means of endoscopic evaluation of polyp size, symptoms, peripheral eosinophil counts, peripheral and local IL-5 levels, eotaxin levels, and eosinophil cationic protein levels. RESULTS: We demonstrated that a single injection of reslizumab up to 3 mg/kg is safe and well tolerated. Blood eosinophil numbers and concentrations of eosinophil cationic protein were reduced up to 8 weeks after treatment in serum and nasal secretions. Individual nasal polyp scores improved only in half of the treated patients for 4 weeks. Responders had increased IL-5 concentrations in nasal secretions at baseline compared with nonresponders, and logistic regression analysis revealed that increased nasal IL-5 levels (>40 pg/mL) predict the response to anti-IL-5 treatment. CONCLUSION: A single injection of anti-IL-5 reduces the size of nasal polyps for 4 weeks in half of the patients, and nasal IL-5 levels predict the response to anti-IL-5 treatment. CLINICAL IMPLICATIONS: Intravenous administration of a humanized anti-human IL-5 mAb is safe and reduces the size of nasal polyps in half of the patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Antibodies, Monoclonal - adverse effects
- Double-Blind Method - adverse effects
- Female - adverse effects
- Humans - adverse effects
- Injections, Intravenous - adverse effects
- Interleukin-5 - antagonists and inhibitors
- Male - antagonists and inhibitors
- Middle Aged - antagonists and inhibitors
- Nasal Mucosa - immunology
- Nasal Polyps - immunology
- Find related publications in this database (Keywords)
- chronic rhinosinusitis
- nasal polyps
- eosinphils
- IL-5
- IL-5 receptor alpha
- anti-IL-5